Prof. Dr. med. Dr. phil.
Matthias Oelke

Mitglied
Klinik für Urologie
St. Antonius Hospital
Möllenweg 22
48599 Gronau/Westfalen
+49 2562 – 915 2100
+49 2562 915 2105

Kernkompetenzen

  • Benignes Prostatasyndrom (Pathophysiologie, Diagnostik und Therapie)
  • Nykturie
  • Harninkontinenz
  • Neuro-Urologie
  • Urodynamik
  • Rekonstruktion des unteren Harntrakts
  • Prostatakarzinom

 

Werdegang

1994-1996 Arzt im Praktikum, Klinik für Allgemein-, Gefäß- und Thoraxchirurgie, Marienhospital Osnabrück
1996-2001 Assistenzarzt, Klinik für Urologie & Kinderurologie, Medizinische Hochschule Hannover
2001 Anerkennung zum deutschen Facharzt für Urologie
2001-2004 Funktionsoberarzt, Klinik für Urologie & Kinderurologie, Medizinische Hochschule Hannover
2003 Europäisches Facharztexamen (EBU Teil 1)
2004 Promotion Urologie, Medizinische Hochschule Hannover (summa cum laude)
2004-2008 Oberarzt und Sektionsleiter Funktionelle & Rekonstruktive Urologie, Klinik für Urologie, Universität Amsterdam, Niederlande
2005 Europäisches Facharztexamen (EBU Teil 2), seitdem Fellow of the European Board of Urology (FEBU)
2008-2017 Oberarzt und Sektionsleiter Funktionelle & Rekonstruktive Urologie, Klinik für Urologie & Kinderurologie, Medizinische Hochschule Hannover
2010 Habilitation Urologie, Medizinische Hochschule Hannover
2016 PhD-Arbeit, Universität Amsterdam, Niederlande
2017 Oberarzt, Klinik für Urologie, Universität Maastricht, Niederlande
Seit 2018 Außerplanmäßiger Professor für Urologie, Medizinische Hochschule Hannover
Seit 2018 Oberarzt, Sektionsleiter Funktionelle Urologie, Leiter des Studien- und Wissenschaftszentrums, Leiter des interdisziplinären Kontinenz- und Beckenbodenzentrums, Klinik für Urologie, Kinderurologie & Urologische Onkologie, St. Antonius-Hospital Gronau
2001 – 2022 17 nationale oder internationale Preise/Auszeichnungen
2002 – 2022 3 nationale oder internationale Forschungsstipendien

 

Mitgliedschaften

  • Deutsche Gesellschaft für Urologie (DGU)
    • Seit 2001 Arbeitskreis Benignes Prostatasyndrom, 2001 – 2014 Schriftführer des Arbeitskreises, 2015 – 2017  Vorsitzender des Arbeitskreises
    • Seit 2009 Arbeitskreis Urologische Funktionsdiagnostik & Urologie der Frau
  • Berufsverband der Deutschen Urologen (BvDU), 2015 – 2017 Kommission Krankenhausärzte
  • European Association of Urologie (EAU), 2004 – 2012 Vorsitzender der Leitliniengruppe Male LUTS, 2004 – 2014 Mitglied des Leitlinienoffice
  • European Board of Urology (EBU)
  • Niederländische Vereinigung für Urologie (NVU)
  • International Continence Society (ICS), seit 2020 Vorsitzender der Leitlinienkommission
  • International Consultation on Incontinence-Research Society (ICI-RS)
  • Forum Urodynamicum Gesellschaft
  • Deutsche Kontinenzgesellschaft
  • Deutsches Prostatakarzinom Konsortium (DPKK)

 

Wissenschaftliche Publikationen

280 Publikationen, Gesamt-Impactfaktor >1.000, h-Index 45, i10-Index 141, >10.000 Zitationen (Stand 30.06.2022)

Wichtige Publikationen zum Thema BPS

  1. Oelke M, Höfner K, Wagner T, Schultheiss D, Jonas U (2000) Changes of urinary incontinence after TURP: A questionnaire based analysis. Akt Urol. 31, 87 – 90.
  2. Oelke M, Höfner K, Wiese B, Grünewald V, Jonas U (2002) Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol. 19: 443 – 452.
  3. Oelke M, Höfner K, Berges RR, Jonas U (2002) Pharmacological treatment of the benign prostatic syndrome (symptomatic BPH) using alpha1-adrenoceptor antagonists. Basic principles and clinical results. Urologe A 41: 425 – 441.
  4. Ückert S, Oelke M, Stief CG, Jonas U, Andersson KE, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol.: 49: 740 – 745.
  5. Oelke M, Höfner K, Jonas U, Ubbink D, de la Rosette JJ, Wijkstra H (2006) Ultrasound measurement of detrusor wall thickness in healthy adults. Neururol Urodyn. 25: 308 – 317.
  6. Oelke M, Höfner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H (2007) Diagnostic accuracy of non-invasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, post-void residual urine, and prostate volume. Eur Urol. 52: 827 – 835.
  7. Oelke M, Höfner K, Jonas U, Laval KU, Tunn U (2007) Terminologie und Diagnostik des benignen Prostatasyndroms. Dt. Ärzteblatt 104: A2261 – 2267.
  8. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 54: 419 – 426.
  9. Oelke M, Mamoulakis C, Ubbink D, de la Rosette J, Wijkstra H (2009) Manual versus automatic bladder wall thickness measurements: a method comparison study. World J Urol. 27: 747 – 753.
  10. Herrmann TRW, Georgiou A, Bach T, Gross AJ, Oelke M (2009) Laser treatments of the prostate vs. TURP/open prostatectomy: Systematic review of urodynamic data. Minerva Urol. 61: 309 – 324.
  11. Herrmann TRW, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ (2010) Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol. 28: 45 – 51.
  12. Oelke M (2010) International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: The need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophy. Neurourol Urodyn. 29: 634 – 639.
  13. Berges R, Oelke M (2011) Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German community-dwelling population aged 50 years or older. World J Urol. 29: 171 – 178.
  14. van Koeveringe GA, Vahabi B, Andersson KE, Kirschner-Hermanns R, Oelke M (2011) Detrusor underactivity: a plea for new approaches to a common bladder dysfunction. Neurourol Urodyn. 30: 723 – 728.
  15. Ückert S, Oelke M (2011) Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 72: 197 – 204.
  16. Oelke M, Madersbacher S (2011) Primary and secondary prevention of benign prostatic hyperplasia – current knowledge and implication for clinical management. Urologe A 50: 1257 – 1264.
  17. Oelke M, Guiliano F, Mirone V, Xu L, Cox D, Viktrup L (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 61: 917 – 925.
  18. Oelke M, Burger M, Castro-Diaz D, Chartier-Kastler E, Jiménez-Cidre MA, McNicholas T, Radziszewski P, Kirby M (2012) Diagnosis and medical treatment of LUTS in adult men: applying specialist guidelines in clinical practice. BJU Int. 110: 710 – 718.
  19. van Kerrebroeck, Haab F, Angulo J, Vik V, Katona F, Garcia-Hernandez A, Klaver M, Traudtner K, Oelke M (2013) Efficacy and safety of solifenacin plus tamsulosin OCAS™ in men with voiding and storage LUTS: results from a phase 2, dose-finding study (SATURN). Eur Urol. 64: 398 – 407.
  20. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette J (2013) EAU Guidelines on the treatment and follow-up of non-neurogenic Male Lower Urinary Tract Symptoms, including Benign Prostatic Obstruction. Eur Urol. 64: 118 – 140.
  21. Oelke M, Weiss JP, Mamoulakis C, Cox D, Ruff D, Viktrup L (2014) Effects of tadalafil on night-time voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: analyses of pooled data from four randomized, placebo-controlled clinical studies. World J Urol. 32: 1127 – 1132.
  22. Eisenhardt A, Schneider T, Cruz F, Oelke M (2014) Consistent and significant improvements of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH – pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 32: 1119 – 1125.
  23. Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A (2014) Treatment satisfaction with tadalafil or tamsulosin versus placebo in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, placebo-controlled study. BJU Int. 114: 568 – 575.
  24. Oelke M, Roehrborn CG, D’Ancona C, Wilson TH, Castro R, Manyak M (2014) Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study. World J Urol. 32: 1133 – 1140.
  25. Oelke M, Roehrborn CG, D’Ancona C, Wilson TH, Castro R, Manyak M (2014) Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. World J Urol. 32: 1141 – 1147.
  26. Oelke M, Berges R, Schläfke S, Burkart M (2014) Fixed dose combination of sabal and urtica improves nocturia in men with LUTS suggestive of BPH – re-evaluation of four controlled clinical studies. World J Urol. 32: 1149 – 1154.
  27. Oelke M, Rademakers KLJ, van Koeveringe GA (2014) Detrusor contraction power parameters (BCI and Wmax) increase with rising bladder outlet obstruction grade in men with lower urinary tract symptoms – results from a urodynamic database analysis to define detrusor underactivity. World J Urol. 32: 1177 – 1183.
  28. Berges R, Höfner K, Gedamke M, Oelke M (2014) Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World J Urol. 32: 1163 – 1170.
  29. Oelke M, Wiese B, Berges R (2014) Nocturia and its impact on health related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older. World J Urol. 32: 1155 – 1162.
  30. Oelke M, Gericke A, Michel MC (2014) Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expt Opin Drug Saf. 13: 1187 – 1197.
  31. Oelke M, Shinghal R, Sontag A, Baygani SK, Donatucci CF (2015) Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo-controlled studies. J Urol. 193: 1581 – 1589.
  32. Osman NI, Chapple CR, Tammela TL, Eisenhardt A, Oelke M (2015) Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 33: 697 – 706.
  33. Vlachopoulos C*, Oelke M*, Maggi M, Mulhall JP, Rosenberg MT, Brock GB, Esler A, Büttner H (2015) Impact of cardiovascular risk factors and related comorbid conditions on the treatment response to tadalafil once-daily in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: an integrated analysis of four randomized, double-blind, placebo-controlled clinical trials. Int J Clin Pract. 69: 1496 – 1507. *contributed equally, corresponding author.
  34. Gratzke C, Bachmann A, Descazeaud A, Drake M, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KA, Gravas S (2015) EAU Guidelines on the assessment of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Eur Urol. 67: 1099 – 1109.
  35. Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, Wehling M (2015) Appropriateness of urological drugs for long-term treatment of lower urinary tract symptoms in the elderly: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 44: 745 – 755.
  36. Oelke M, Speakman M, Desgrandchamps F, Mamoulakis C (2015) Acute urinary retention rates in the general male population and in adult men with lower urinary tract symptoms participating in pharmacotherapy trials – a literature review. Urology. 86: 654 – 665.
  37. Oelke M, Rademakers KL, van Koeveringe GA (2016) Unravelling detrusor underactivity: development of a bladder outlet obstruction – bladder contractility nomogram in adult male patients with lower urinary tract symptoms. Neurourol Urodyn. 35: 980 – 986.
  38. McVary KT, Peterson A, Donatucci C, Baygani S, Henneges C, Clouth J, Wong D, Oelke M (2016) Differential impact of storage and voiding symptoms on quality-of-life during therapy for LUTS associated with BPH: structural equation modeling using an integrated randomized controlled trial tadalafil database. J Urol.: 196: 824 – 830.
  39. Oelke M, Anderson P, Wood R, Holm-Larsen T (2016) Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real-life practice database containing 8659 European and US-American patients. Int J Clin Pract. 70: 940 – 949.
  40. Rademakers KL, van Koeveringe GA, Oelke M (2016) Detrusor underactivity in men with LUTS/BPO: characterization and potential impact on indications for surgical treatment of the prostate. Curr Opin Urol. 26: 3 – 10.
  41. Rademakers KL, van Koeveringe GA, Oelke M (2017) Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men. World J Urol. 35: 153 – 159.
  42. Oelke M, Wagg A, Takita Y, Büttner H, Viktrup L (2017) Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged 75 years or older: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. BJU Int. 119: 793 – 803.
  43. Oelke M, De Wachter S, Drake MJ, Giannantoni A, Kirby M, Orme S, Rees J, van Kerrebroeck P, Everaert K (2017) A practical approach to the management of nocturia. Int J Clin Pract. 71: e13027.
  44. Oelke M, Fangmeyer B, Zinke J, Witt JP (2018) Nykturie beim benignen Prostatasyndrom. Akt Urol. 49: 319 – 327.
  45. D’Ancona C, Haylen BT, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, Hamid R, Homma Y, Marcelissen T, Rademakers K, Schizas A, Singla A, Soto I, Tse V, de Wachter S, Herschorn S (2019) The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 38: 433 – 477.
  46. Oelke M, Bschleipfer T, Höfner K (2019) Hartnäckige Mythen zum Thema BPS – und was davon wirklich stimmt! Urologe A 58: 271 – 283.
  47. Madersbacher S, Roehrborn CG, Oelke M (2020) The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). BJU Int. 126: 317 – 326.
  48. Abranches-Monteiro L, Hamid R, D’Ancona D, AlHasso A, Dmochowski R, Ecclestone H, Al Mousa R, Onur R, Shah S, Vasudeva P, Vilas V, Oelke M (2020) The International Continence Society (ICS) report on the terminology for male lower urinary tract surgery. Neurourol Urodyn. 39: 2072 – 2088.
  49. D’Agate S, Chavan C, Manyak M, Palacios-Moreno JM, Oelke M, Michel MC, Roehrborn CG, Della Pasqua O (2021) Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. Br J Clin Pharmacol.: 87: 2777 – 2789.
  50. D’Agate S, Chavan C, Manyak M, Palacios-Moreno JM, Oelke M, Michel MC, Roehrborn CG, Della Pasqua O (2021) Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression. World J Urol. 39: 2635 – 2643.

© 2021 by Deutsche Gesellschaft für Urologie e.V. 
Uerdingen Str. 64 | 40474 Düsseldorf